Anta Sports Expands Global Footprint With Strategic Puma Stake 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
NORTHBROOK, Ill., Feb. 11, 2016 -- Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted and flexible molecular diagnostics, announced today that it will report its results for the fourth quarter ended December 30, 2015 after the market close on Wednesday, February 24, 2016. The company will also hold a live investor conference call and webcast at 5pm Eastern Time.
Conference Call & Webcast
Wednesday, February 24 @ 5pm Eastern Time
| Domestic: | 888-438-5453 |
| International: | 719-325-2144 |
| Passcode: | 8370643 |
| Webcast: | http://www.nanosphere.us/investors |
| Replays – Available through March 9, 2016 | |
| Domestic: | 877-870-5176 |
| International: | 858-384-5517 |
| Passcode: | 8370643 |
About Nanosphere, Inc.
Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company’s versatile technology platform, the Verigene® System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplexed diagnostic test. The combination of this innovative technology and Nanosphere’s customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.
Contacts Investors: Michael Rice, LifeSci Advisors 646-597-6979 [email protected] Media: Zachary Crowther, Director of Marketing 847-400-9074 [email protected]
